Glaukos(US:GKOS) ZACKS·2025-10-30 17:26Core Insights - Glaukos Corporation reported a narrower adjusted loss of 16 cents per share for Q3 2025, better than the Zacks Consensus Estimate of a 27-cent loss and improved from a 28-cent loss in the same quarter last year [1] - The company achieved revenues of $133.5 million, reflecting a 38% year-over-year increase and surpassing the Zacks Consensus Estimate by 9.5% [2] Revenue Details - Net sales for Glaucoma reached $110.2 million, up 45% year over year, while Corneal Health sales totaled $23.3 million [3] Margin Analysis - Gross profit increased by 41.3% year over year to $104.7 million, with an adjusted gross margin of 84%, up from 82% in the previous year [4] - Selling, general, and administrative expenses rose by 30% year over year to $83 million, while research and development expenses increased by 10% to $38.1 million [4] Operating Performance - The operating loss decreased to $16.4 million from $24.7 million in the prior year, with an adjusted operating loss of $9.3 million, an improvement from the $18.4 million loss in the same quarter last year [5] Financial Update - At the end of Q3 2025, Glaukos had cash and cash equivalents and short-term investments totaling $277.5 million, slightly down from $278.6 million at the end of Q2 2025 [6] 2025 Guidance - The company raised its 2025 revenue guidance to a range of $490-$495 million, up from the previous estimate of $480-$486 million, with a loss per share estimate of 90 cents, indicating a 51.6% year-over-year improvement [7] Strategic Developments - The FDA approval of Epioxa represents a significant advancement, introducing a next-generation, incision-free therapy for keratoconus, enhancing Glaukos' rare disease portfolio [10] - The company is focused on disciplined capital allocation, robust R&D investment, and the upcoming Huntsville facility to support innovation and manufacturing scale, positioning itself for sustainable growth [11]